Metrics as of 10/17/2026, 07:41 AM (Berlin time), refresh in progress.
Bausch + Lomb Stock
Bausch + Lomb Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- Canada
- CEO
- Thomas J. Appio
- Employees
- 13,000
- Market cap
- $5.9 B
- IPO
- 06/05/2022
Bausch + Lomb Corporation is a leading global eye health company headquartered in Vaughan, Canada. The company is listed on the NYSE and was founded in 1853. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. Through the Vision…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Bausch + Lomb stock: price history
1D
-1.0%
1W
-4.7%
1M
-3.4%
6M
-2.0%
YTD
-3.5%
1Y
+11.0%
2Y
-20.6%
5Y
–
10Y
–
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~43% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Bausch + Lomb
Analyst assessment of Bausch + Lomb
PRICE TARGET LOW
US$16.00
CONSENSUS
US$20.83
MEDIAN
US$22.00
PRICE TARGET HIGH
US$24.00
0
STRONG BUY
8
BUY
8
HOLD
1
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 15/09/2026
Bausch + Lomb stock metrics
P/E
-34.48
P/B
0.92
EV/EBITDA
14.34
RETURN ON EQUITY
-0.2%
NET MARGIN
-1.0%
DEBT/EQUITY
0.8
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
12.9%
FLOAT SHARES
46,060,030
AVG. DAILY VOLUME (30D)
475,674
Insider transactions (SEC)
PAUL LAURENCE E
Chersi Robert J
Trebbi Barbara
Munsch Frederick
VON ESCHENBACH ANDREW C.
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Bausch + Lomb stock
What does Bausch + Lomb do?
Bausch + Lomb Corporation is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in Canada.
The CEO is Thomas J. Appio, the company employs around 13,000 people.
The IPO was on 06/05/2022; the stock trades on NYSE under the ticker BLCO.
What do analysts say about Bausch + Lomb stock?
17 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$20.83, ranging from US$16.00 to US$24.00, with a median of US$22.00.
This is an external assessment, not a statement by Market Jury.
When does Bausch + Lomb report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 43% stronger than usual.
Does Bausch + Lomb pay a dividend?
No, Bausch + Lomb currently does not pay a dividend.
Which stocks are comparable to Bausch + Lomb?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Sartorius, Solventum, Baxter International and Cooper Companies.
How can I get Bausch + Lomb stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bausch + Lomb against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.